Edition:
United States

GlaxoSmithKline PLC (GSK.N)

GSK.N on New York Stock Exchange

43.91USD
4:02pm EDT
Change (% chg)

$-0.16 (-0.36%)
Prev Close
$44.07
Open
$44.04
Day's High
$44.09
Day's Low
$43.87
Volume
476,257
Avg. Vol
729,534
52-wk High
$45.58
52-wk Low
$37.20

Latest Key Developments (Source: Significant Developments)

Glaxosmithkline starts phase III study for nasal polyps drug
5:06am EDT 

June 27 (Reuters) - Glaxosmithkline Plc ::GSK starts phase III study with Mepolizumab in patients with nasal polyps.Key secondary endpoint is time to first actual surgery for nasal polyps by week 52​.Study is anticipated to complete in 2019.Study will assess efficacy and safety of subcutaneous Mepolizumab 100mg compared to placebo.  Full Article

GSK CEO Walmsley pursuing sale of Maxinutrition brand - Sky News
Thursday, 22 Jun 2017 03:33pm EDT 

June 22 (Reuters) - :Glaxosmithkline Plc CEO Emma Walmsley is pursuing a sale of Maxinutrition, a nutritional products brand - Sky News.  Full Article

GSK says Shingrix phase 3 study met main goal
Wednesday, 21 Jun 2017 09:13am EDT 

June 21 (Reuters) - Glaxosmithkline Plc ::Presents positive results from phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's advisory meeting.Study met its primary objective of demonstrating non-inferior immune response.Shingrix was well-tolerated in both study groups when assessed up to one month after second dose of Shingrix.  Full Article

GlaxoSmithKline announces positive results from two phase III studies of Tafenoquine​
Monday, 12 Jun 2017 07:09am EDT 

June 12 (Reuters) - GlaxoSmithKline Plc :‍GSK and Medicines for Malaria Venture announced positive results from two phase III studies of Tafenoquine​.Tafenoquine is an investigational 8-aminoquinoline, for prevention of relapse of plasmodium vivax (p.vivax) malaria​.Headline results show single-dose of 300mg tafenoquine reduced risk of relapse in patients with p.vivax malaria​.‍Study met its primary endpoint.‍study showed that a statistically significant greater proportion of patients treated with tafenoquine (60%) remained relapse-free over 6-month follow-up period​.‍GSK plans to progress regulatory filings for prevention of relapse of p. Vivax malaria later in 2017​.  Full Article

GSK says ViiV Healthcare submits 2-drug HIV regimen application to EMA,U.S. FDA
Friday, 2 Jun 2017 02:00am EDT 

June 2 (Reuters) - Glaxosmithkline Plc ::ViiV submits first 2-drug hiv regimen application.‍Priority review voucher submitted in US with anticipated target action date of 6 months​.‍EU and US submissions for single tablet combining dolutegravir and rilpivirine​.‍$130 million cost of voucher will be reported as an research and development expense in GSK's q2 2017 adjusted results​.Under prescription drug user fee act, anticipated target action date is six months after receipt of application by FDA.Use of dolutegravir and rilpivirine as a two-drug regimen for hiv-1 maintenance therapy is investigational and not approved anywhere in world.  Full Article

Adaptimmune Therapeutics says initiated study of NY-ESO SPEAR T‑cells
Thursday, 25 May 2017 08:00am EDT 

May 25 (Reuters) - Adaptimmune Therapeutics Plc :Adaptimmune Therapeutics Plc - initiated study of NY-ESO SPEAR T‑cells targeting NY-ESO in combination with keytruda in patients with multiple myeloma.Adaptimmune Therapeutics Plc - Adaptimmune is developing NY-ESO SPEAR T-cell program under a strategic collaboration agreement with GSK.  Full Article

Kuehne und Nagel and GlaxoSmithKline expand partnership with new UK domestic distribution contract
Wednesday, 17 May 2017 11:37am EDT 

May 17 (Reuters) - KUEHNE UND NAGEL INTERNATIONAL AG :KUEHNE + NAGEL AND GLAXOSMITHKLINE EXPAND PARTNERSHIP WITH NEW UK DOMESTIC DISTRIBUTION CONTRACT.  Full Article

Paulson & Co Inc takes share stake in Amazon, Arconic - SEC filing
Monday, 15 May 2017 05:33pm EDT 

May 15 (Reuters) - Paulson & Co Inc : :Paulson & Co Inc takes share stake in Amazon of 5,500 shares - SEC filing.Paulson & Co Inc takes share stake of 983,300 shares in Arconic Inc.Paulson & Co Inc takes share stake of 78,101 shares in Sarepta Therapeutics Inc.Paulson & Co Inc ups share stake in Glaxosmithkline PLC by 40.2 percent to 415,100 Sponsored ADR.Paulson & Co Inc - Change in holdings are as of March 31, 2017 and compared with the previous quarter ended as of Dec 31, 2016.  Full Article

Ionis Pharma announces Phase 3 NEURO-TTR study of inotersen meets both primary endpoints
Monday, 15 May 2017 07:00am EDT 

May 15 (Reuters) - Ionis Pharmaceuticals Inc :Ionis pharmaceuticals announces phase 3 neuro-ttr study of inotersen (ionis-ttr rx) meets both primary endpoints.Says statistically significant differences were also observed for both endpoints at eight months.Ionis pharmaceuticals - long-term safety and efficacy data with inotersen currently being collected in open-label extension of phase 3 neuro-ttr study.Says review of full data package from neuro-ttr study by ionis and gsk is ongoing.Says preparation of regulatory marketing applications for inotersen is underway.Ionis pharmaceuticals - gsk has option to license inotersen following review of additional data and prior to submission of regulatory applications.  Full Article

GlaxoSmithKline announces positive results for asthma drug study
Friday, 5 May 2017 07:38am EDT 

May 5 (Reuters) - Glaxosmithkline Plc ::Announced positive results from innovative Salford Lung Study (SLS) in asthma.Relvar Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care.Study showed significantly more asthma patients initiated on treatment with Relvar Ellipta achieved improvement in their asthma control.At 24 weeks a significantly higher percentage of patients with asthma achieved better control of their asthma (71 pct) measured by asthma control test (ACT).Statistically significant findings were also seen at 12, 40 and 52 weeks.Serious adverse events of pneumonia by randomised group were reported by 39 patients (ff/vi arm 23, 1 pct; usual care arm 16, <1 pct).  Full Article

More From Around the Web

BRIEF-Glaxosmithkline starts phase III study for nasal polyps drug

* GSK starts phase III study with Mepolizumab in patients with nasal polyps